13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Clover Ascites

    Acronym: 

    TRAIL Trimer

    ACTRN/NCT /ethics: 

    NCT03869697

    Scientific title: 

    Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Malignant Ascites
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2019-08-26
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Malignant Ascites
    Cancer Stage All stages
    Anticipated Start Date 2019-08-26
    Anticipated End Date

    Trial Summary

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over 2 to 3 days (MAD)for the treatment of cancer patients with symptomatic malignant pleural effusions requiring drainage.

    Lay Summary

    Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

    Sponsor / Cooperative group

    Clover Biopharmaceuticals AUS

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Ganessan Kichenadasse Recruiting